Last reviewed · How we verify
Thrombolytic Agent
At a glance
| Generic name | Thrombolytic Agent |
|---|---|
| Also known as | eptifibatide, thrombectomy |
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE (NA)
- Optimizing Reperfusion to Improve Outcomes and Neurologic Function (PHASE2, PHASE3)
- Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter
- Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke (NA)
- Safety and Efficacy of J147 in Acute Ischemic Stroke (PHASE2)
- Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thrombolytic Agent CI brief — competitive landscape report
- Thrombolytic Agent updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI